ABSTRACT
Objective:To explore the efficacy and safety of neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients.Methods:Six patients with NSCLC who were diagnosed as ⅢA and received two cycles of neoadjuvant chemoimmunotherapy and surgery between September 2019 and January 2020 were described in this study.Results:Five of them experienced AEs during neoadjuvant therapy. All of them received surgery and achieved an MPR of 50%. No viable tumor cells were found in the tissues of one patient. One patient with a small bronchopleural fistula after lobectomy.Conclusion:Neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients is safe and efficient. Long-term outcomes of neoadjuvant chemoimmunotherapy combined with surgery should be further validated.
ABSTRACT
National investment in lung cancer related research projects increased during the past few years , the funding from National Natural Science Foundation of China(NSFC) also have an upward trend year by year.As the statistical analysis shows, the NSFC devoted a lot to the projects of lung cancer in both numbers and amounts from 2006 to 2015, and grows rapid-ly.General projects and youth fund projects are predominant types of funds; medical science department is the majority of all departments; Hot research projects include MicroRNA, EMT, lung cancer stem cell, apoptosis, lung cancer genomics,angio-genesis of lung cancer,EGFR, lncRNA, Wnt pathway, etc.The autophagy、lncRNA and Wnt pathway related researchs have gone through the process from scratch, and investments have continued to increase.The purpose of this study is to analyze the distribution and hotspot research of NSFC funded projects in the field of lung cancer in China.